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Abstract
Background
Biomarkers are potentially useful in assessment of outcomes in patients with cirrhosis, but
information is very limited. Given the large number of biomarkers, adequate choice of which
biomarker(s) to investigate first is important.
Aim
Analysis of potential usefulness of a panel of urinary biomarkers in outcome assessment
in cirrhosis.
Patients and Methods
Fifty-five patients with acute decompensation of cirrhosis were studied: 39 had Acute Kid-
ney Injury (AKI) (Prerenal 12, type-1 HRS (hepatorenal syndrome) 15 and Acute Tubular
Necrosis (ATN) 12) and 16 acute decompensation without AKI. Thirty-four patients had
Acute-on-chronic liver failure (ACLF). A panel of 12 urinary biomarkers was assessed,
using a multiplex assay, for their relationship with ATN, ACLF and mortality.
Results
Biomarker with best accuracy for ATN diagnosis was NGAL (neutrophil-gelatinase associat-
ed lipocalin): 36 [26-125], 104 [58-208] and 1807 [494-3,716] μg/g creatinine in Prerenal-
AKI, type-1 HRS and ATN, respectively; p<0.0001 (AUROC 0.957). Other attractive bio-
markers for ATN diagnosis were IL-18, albumin, trefoil-factor-3 (TFF-3) and glutathione-S-
transferase-π (GST-π) Biomarkers with less accuracy for ATN AUCROC<0.8 were β2-
microglobulin, calbindin, cystatin-C, clusterin and KIM-1 (kidney injury molecule-1). For
ACLF, the biomarker with the best accuracy was NGAL (ACLF vs. No-ACLF: 165 [67-676]
and 32 [19-40] μg/g creatinine; respectively; p<0.0001; AUROC 0.878). Interestingly, other
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biomarkers with high accuracy for ACLF were osteopontin, albumin, and TFF-3. Biomarkers
with best accuracy for prognosis were those associated with ACLF.
Conclusions
A number of biomarkers appear promising for differential diagnosis between ATN and other
types of AKI. The most interesting biomarkers for ACLF and prognosis are NGAL, osteo-
pontin, albumin, and TFF-3. These results support the role of major inflammatory reaction in
the pathogenesis of ACLF.
Introduction
Biomarkers are important to help in decision making and outcome prediction of chronic con-
ditions. For many years, clinical decisions in patients with cirrhosis have relied on the use of
simple liver function tests, either used alone or in combination [1,2]. Moreover, because cirrho-
sis is frequently associated with failure of extrahepatic organs, a condition known as Acute-on-
chronic liver failure (ACLF), biomarkers of function of organs other than the liver may also be
of major importance in therapeutic decisions and prediction of prognosis [3,4]. In this regard,
serum creatinine has been extensively used in the assessment of kidney dysfunction associated
with cirrhosis despite its limitations as an estimate of glomerular filtration rate (GFR) [5]. Nev-
ertheless, serum creatinine is not able to distinguish between the different causes of kidney dys-
function that can affect patients with cirrhosis. Therefore, urinary biomarkers are obviously
needed in the differential diagnosis of kidney failure, particularly because some of the causes
have specific management and there are no objective parameters useful in this context. Finally,
since cirrhosis is frequently associated with a proinflammatory state, biomarkers of systemic
inflammation should also be explored. Overall, there is a need for new and accurate biomarkers
in the clinical assessment of patients with cirrhosis.
The discovery of biomarkers has advanced rapidly in the field of kidney diseases because of
the easy access to the analysis of fluid that is coming out directly from the kidney [6,7]. By con-
trast, the investigation of biomarkers from the liver is going at a much slower pace because of
the difficulty in accessing the fluid output from the liver, among other potential reasons. None-
theless, some markers derived from non-renal origin may appear in the urine through glomer-
ular filtration. For example, several studies have convincingly shown that neutrophil-gelatinase
associated lipocalin (NGAL) in addition of being synthetized in the kidney under conditions of
tubular injury is synthetized in the liver as a result of liver cell injury or liver regeneration [8–
10]. Therefore, this protein may be a potential biomarker of liver injury.
There are only a handful of studies evaluating urinary biomarkers in patients with liver
diseases, particularly cirrhosis [11–15]. These studies have investigated either a single bio-
marker or a small number of biomarkers. Therefore, the potential usefulness of some bio-
markers has not been investigated yet. Moreover, the existing information in cirrhosis is
exclusively focused on the assessment of biomarkers in the differential diagnosis of the cause
of Acute Kidney Injury (AKI), but their possible role in the evaluation of other outcomes has
not been assessed. In this context, we evaluated a panel of 12 biomarkers identified in animal
studies of AKI. The panel includes the most commonly investigated biomarkers in the field of
AKI (NGAL, kidney injury molecule-1—KIM-1—and interleukin-18—IL-18–). Moreover,
the panel has the six biomarkers recently proposed by the Food and Drug Administration and
the European Medicines Evaluation Agency for use as indicators of nephrotoxic AKI through
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the Critical Path Initiave (albumin, β2-microglobulin, clusterin, cystatin C, KIM-1 and trefoil
factor-3-TFF-3-) [16]. Finally, the panel also includes some proinflammatory molecules, such
as monocyte chemoattractant protein-1 (MCP-1) and osteopontin, together with calbindin
and glutathione-S-transferase-π (GST-π). In addition of investigating the role of all these bio-
markers in the evaluation of AKI, their possible role in the assessment of ACLF as well as
prognosis has been evaluated.
Patients and Methods
Patient population and study design
This study was presented and approved by the Ethics Committee of Hospital Clinic registration
number 2012/7646. The creation of the biobank collection was presented and approved by the
Ethics Committee registration number 2011/6689. All patient samples were included and
stored in the Biobank as required by Spanish Law. All patients signed a written informed con-
sent document and gave permission for samples to be used in the study following current na-
tional and institutional guidelines for sample storage and usage for research purposes.
Fifty-five patients admitted to the Liver Unit of the Hospital Clínic of Barcelona for the
management of an acute decompensation of cirrhosis were included in the study. These pa-
tients were selected from a prospective database which includes all consecutive patients with
cirrhosis admitted to hospital for an acute decompensation of the disease since December
2011. The only exclusion criteria are: 1) chronic hemodialysis before admission; (2) previous
liver and/or kidney transplantation; (3) hepatocellular carcinoma outside the Milan criteria or
any other advanced malignancy; and (4) lack of informed consent. Because the study was an
exploratory analysis of the relationship between urinary biomarkers and clinical outcomes, and
AKI was the primary outcome, we selected from the database a sizeable number of consecutive
patients with AKI due to three different causes, prerenal failure, type-1 hepatorenal syndrome
(HRS) and acute tubular necrosis (ATN), as well as patients with an acute decompensation of
cirrhosis who neither had AKI at admission nor developed it during hospitalization. A total of
55 patients were included, 39 with AKI and 16 with acute decompensation of cirrhosis without
AKI. A group of 6 healthy volunteers was also studied. In patients with AKI the collection of
urine was performed at the time of diagnosis of AKI (median time between diagnosis and urine
collection was 1 day—range 0 to 2 days). In patients without AKI, urine was collected at the
time of admission to hospital. Samples were centrifuged at 1,000 rpm for 10 min and the super-
natant stored in cryovials at -80°C until analysis. All clinical information of patients including
baseline demographic, clinical, and biochemical variables and outcomes during hospitalization
was collected prospectively using specifically designed electronic case report forms.
Clinical outcomes and definitions
AKI was defined using the AKIN criteria, evaluated in intervals of 48–72 h throughout hospi-
talization, as an increase in serum creatinine of0.3 mg/dl or50% over the baseline value
obtained in the previous 48–72 h [17]. For the diagnosis of AKI at admission the value used as
baseline was the most recent stable serum creatinine value available within the previous 3
months [13,15].
Prerenal-AKI, type-1 HRS, and ATN were defined as previously reported [11,18]. Treat-
ment of different types of AKI was performed according to international guidelines [19,20].
Definition and grading of ACLF was done according to the CANONIC study [4]. Survival was
evaluated at 3 months.
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Measurement of urinary biomarkers
Bio-Plex Pro RBMHuman Kidney Toxicity panel 1 (calbindin, clusterin, GST-π, IL-18, KIM-1,
and MCP-1) and panel 2 (albumin, β2-microglobulin, cystatin C, NGAL, osteopontin, and TFF-
3) were used according to the manufacturer protocol (Bio-Rad Laboratories, Hercules, CA).
Briefly, urine samples were centrifuged at 500 x g for 5 min and diluted 1:4 for the panel 1 and
1:50 for the panel 2 assays. After blockade of nonspecific binding sites, 30 microliters of stan-
dards, controls or diluted samples were added to 96-well plates and incubated with 10 mL of
fluorescently dyed magnetic microspheres covalently coupled to specific antibodies for the de-
sired biomarkers. Next, the plates were incubated for 1 h at room temperature and washed three
times with wash buffer. Afterwards, 40 mL of biotinylated detection antibody was added to the
wells and the plates were incubated for an additional hour at room temperature. The final detec-
tion complex was formed with the addition of streptavidin-phycoerythrin conjugated. The medi-
an relative fluorescence units from the antibody reactions were acquired using a Luminex 200
analyzer (Luminex, Austin, TX, USA) and the Bio-Plex Manager Software (v. 6.0; Bio-Rad Labo-
ratories, Hercules, CA). The urinary biomarkers were indexed to urinary creatinine for all analy-
ses to adjust for variability in urine concentration. Since some values of albumin concentration
obtained with the multiplex assay were above the upper limit of detection, all albumin measure-
ments were repeated using the ADVIA Chemistry Microalbumin_2 immunoturbidimetry meth-
od, enhanced with polyethylene glycol, (Siemens Healthcare Diagnostics, Deerfield, IL).
Statistical analysis
Comparisons of continuous variables between groups were made with ANOVA or Kruskal-
Wallis, while comparison between specific groups was made with post-tests. Categorical vari-
ables were compared with chi-square test. The area under the receiver-operating characteristic
curves (AUCROC) was used to assess the relationship between each biomarker and every one
of the specific outcomes. To assess the relationship between biomarkers and ATN, patients
with AKI were divided into those with ATN and those without ATN (i.e Prerenal plus type-1
HRS). All statistical analyses were performed using SPSS 20.0 software. Biomarker values are
expressed as median and interquartile ranges. The significance level for all statistical tests was
set at 0.05 two-tailed.
Results
Baseline characteristics of patients
The baseline characteristics of patients included in the study are shown in Table 1. Most pa-
tients had advanced cirrhosis as indicated by markedly abnormal liver function tests and high
Child-Pugh and MELD scores together with impairment of kidney function. Moreover, 62% of
patients fulfilled the criteria of ACLF at the time of inclusion in the study.
Thirty-nine of the 55 (71%) patients had AKI. AKI was stage 1 in 13 patients (AKI-1A in
one patient and AKI-1B in 12 patients) [18,21], stage 2 in 15, and stage 3 in 11 patients. The
comparison of demographic, clinical, and laboratory variables between patients with and with-
out AKI is shown in Table A in S1 File. The type of AKI was Prerenal in 12 patients, type-1
HRS in 15 patients, and ATN in the remaining 12 patients. Table 2 shows the characteristics of
patients categorized according to the presence and type of AKI. Patients with ATN and those
with type-1 HRS had more marked impairment of liver, kidney, and circulatory function com-
pared to patients with Prerenal-AKI or no AKI. Among the four groups of patients, the greatest
impairment of liver and kidney function tests and systemic hemodynamics was observed in pa-
tients with ATN.
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Urinary biomarkers and relationship with Acute Kidney Injury
We first analyzed the relationship between the different urinary biomarkers and the presence
or absence of AKI. Median urinary concentrations of NGAL, osteopontin, MCP-1, albumin,
and TFF-3 in patients with AKI were significantly higher compared to those of patients without
AKI (Table 3). By contrast, there were no significant differences between patients with and
without AKI with respect to the urinary concentrations of KIM-1, GST-π, cystatin C, calbindin,
β2-microglobulin, IL-18, and clusterin. Remarkably, when patients were categorized according
to AKI stages the urinary levels of most biomarkers were not significantly different among the
different stages (Table 4). The only two biomarkers that were significantly different across AKI
stages were MCP-1 and albumin.
In sharp contrast with the lack of differences in most biomarkers among different AKI stages,
when patients were classified into 4 categories according to the presence and type of AKI there
were statistically significant differences in all biomarkers among the four groups, except for clus-
terin (Table 5). As a whole, however, there was overlap of biomarker levels between the different
categories. In all biomarkers, the highest median values were found in patients with ATN and
the lowest in patients without AKI or with Prerenal-AKI. Overall, in patients with type-1 HRS
biomarker levels had intermediate values between those of patients with ATN and Prerenal-AKI.
The differential diagnosis between ATN and the other two types of AKI is often difficult in
clinical practice but is very important in guiding therapeutic interventions. Therefore, we next
Table 1. Demographic, clinical data and liver and kidney function of all patients included.
Age, yr 58 ± 10
Male, n (%) 43 (78%)
Chronic impairment of kidney function, n (%)* 3 (5.5%)
Etiology of cirrhosis, n: Alcoholic /hepatitis C/ other 26/19/10
Norﬂoxacin prophylaxis 10 (18%)
Treatment with beta-blockers 20 (36%)
Presence of ascites 46 (84%)
Presence of encephalopathy 18 (33%)
Presence of bacterial infection 28 (51%)
Presence of shock 12 (22%)
Serum bilirubin (mg/dL) 6.6 ± 10.5
Serum albumin (g/L) 29.0 ± 6.1
INR 1.8 ± 0.6
MELD score 23 ± 9
Child-Pugh score 9.2 ± 1.9
ACLF** 34 (62%)
Serum creatinine (mg/dL) 2.3 ± 1.6
Serum sodium (mEq/L) 132 ± 6
Mean arterial pressure (mmHg) 76 ± 13
Blood leukocytes (x109/L) 8.3 ± 5.6
C-reactive protein (mg/dL) 4.3 ± 3.7
Values are mean ± SD or number and percentages.
* Parenchymal nephropathy in 2 patients and type-2 hepatorenal in 1 patient.
INR, international normalized ratio; MELD, model for end-stage liver disease.
**ACLF, Acute-on-chronic liver failure, ACLF grade I in 19 patients, grade II in 7 patients and grade III in
8 patients.
doi:10.1371/journal.pone.0128145.t001
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assessed the ability of biomarkers in the differential diagnosis of ATN from other types of AKI.
The predictive accuracy of each of the biomarkers to differentiate ATN from the other two
types of AKI was calculated. As shown in Table 6, the biomarker with the highest predictive ac-
curacy for ATN diagnosis was NGAL with an AUCROC of 0.957. The best cut-off level of
Table 2. Characteristics of patients according to the presence and type of AKI.
No AKI (n = 16) Prerenal (n = 12) HRS Type 1 (n = 15) ATN (n = 12) P
Age, yr 58 ± 10 63 ± 6 59 ± 11 50 ± 9 0.006
Male, n (%) 13 (81%) 9 (75%) 14 (93%) 7 (58%) 0.176
Alcoholic cirrhosis 6 (38%) 7 (58%) 8 (53%) 5 (42%) 0.275
Presence of ascites 12 (75%) 9 (75%) 15 (100%) 10 (83%) 0.216
Presence of encephalopathy 3 (19%) 2 (17%) 5 (33%) 8 (67%) 0.028
Presence of bacterial infection 8 (50%) 0 (0%) 9 (60%) 11 (92%) < 0.0001
Serum bilirubin (mg/dL) 1.9 ± 0.9 1.8 ± 1.1 5.5 ± 7.4 19.3 ± 15.1 < 0.0001
INR 1.5 ± 0.4 1.5 ± 0.3 1.9 ± 0.6 2.1 ± 0.9 0.019
MELD score 13 ± 4 20 ± 5 29 ± 5 31 ± 7 < 0.0001
Child-Pugh score 8.6 ± 1.5 8.3 ± 1.9 9.9 ± 1.9 10.3 ± 1.6 0.012
Serum creatinine (mg/dL) 0.7 ± 0.2 2.3 ± 1.1 3.1 ± 0.8 3.3 ± 2.2 < 0.0001
Serum sodium (mEq/L) 135 ± 5 133 ± 6 129 ± 7 131 ± 6 0.075
Mean arterial pressure (mmHg) 84 ± 14 76 ± 14 73 ± 9 68 ± 9 0.005
Blood leukocytes (x109/L) 5.9 ± 3.1 6.6 ± 3.6 7.3 ± 5.1 14.1 ± 6.8 < 0.0001
C-reactive protein (mg/dL) 3.2 ± 3.3 3.3 ± 4.6 6.7 ± 4.2 3.7 ± 2.1 0.094
Urine sodium (mEq/L) 46 ± 43 31 ± 22 14 ± 23 32 ± 31 0.062
FENa (%) 0.3 ± 0.4 0.5 ± 0.4 0.3 ± 0.7 2.1 ± 3.3 0.015
Urine protein (mg/L) 126 ± 68 346 ± 615 285 ± 365 1357 ± 1776 0.005
Urine osmolarity (mOsmol/kg) 499 ± 140 405 ± 164 369 ± 51 336 ± 99 0.011
Values are mean ± SD or number and percentages.
AKI, acute kidney injury; HRS, hepatorenal syndrome; ATN, acute tubular necrosis; INR, international normalized ratio; MELD, model for end-stage
liver disease.
doi:10.1371/journal.pone.0128145.t002
Table 3. Values of urinary biomarkers according to diagnosis of AKI.
Urinary Biomarkers No AKI (n = 16) AKI (n = 39) p
NGAL (μg/g creat) 30 (17–41) 118 (38–617) < 0.0001
Osteopontin (μg/g creat) 1456 (715–3210) 5471 (2345–11983) < 0.0001
MCP-1 (μg/g creat) 0.2 (0.1–1.4) 2.2 (0.7–5.3) 0.001
Albumin (mg/g creat) 3 (1–7) 39 (8–128) 0.001
TFF-3 (μg/g creat) 582 (367–1665) 2474 (840–4067) 0.001
KIM-1 (μg/g creat) 0.5 (0.3–1.4) 1.2 (0.4–2.6) 0.111
GST-π (μg/g creat) 3 (1–16) 6 (2–43) 0.129
Cystatin C (μg/g creat) 24 (12–45) 37 (15–135) 0.129
Calbindin (μg/g creat) 71 (26–150) 27 (6–141) 0.195
β2-microglobulin (μg/g creat) 51 (13–140) 76 (5–590) 0.447
IL-18 (ng/g creat) 21 (16–35) 29 (14–129) 0.684
Clusterin (μg/g creat) 9 (2–38) 9 (1–26) 0.926
Values are expressed as median and IQR.
AKI, acute kidney injury.
doi:10.1371/journal.pone.0128145.t003
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NGAL to differentiate ATN from other types of AKI was of 294 μg/g creatinine. Eleven out of
the 12 patients with ATN had a urinary NGAL value above this threshold. Biomarkers with sta-
tistically significant AUCROC for ATN diagnosis above 0.80 were IL-18, albumin, TFF-3, and
GST-π.
Biomarkers and relationship with ACLF
We then analyzed the relationship between the different urinary biomarkers and the presence
or absence of ACLF. Median urinary concentrations of NGAL, osteopontin, albumin, MCP-1,
TFF-3, KIM-1, and GST-π in patients with ACLF were significantly higher compared to those
Table 4. Values of urinary biomarkers according to AKI stage at diagnosis of AKI.
Urinary Biomarkers AKI-1 (n = 13) AKI-2 (n = 15) AKI-3 (n = 11) p
NGAL (μg/g creat) 187 (31–430) 111 (58–424) 437 (92–2515) 0.259
Osteopontin (μg/g creat) 4927 (1925–15345) 4868 (2704–7280) 6436 (3501–15772) 0.499
MCP-1 (μg/g creat) 1.2 (0.3–3.3) 2.0 (0.9–2.9) 8.2 (2.5–14.7) 0.015
Albumin (mg/g creat) 16 (2–104) 17 (3–66) 319 (20–381) 0.029
TFF-3 (μg/g creat) 2474 (427–4548) 2632 (1893–4017) 2039 (553–4753) 0.670
KIM-1 (μg/g creat) 0.6 (0.1–3.5) 1.2 (0.6–1.7) 1.6 (0.3–3.7) 0.559
GST-π (μg/g creat) 4 (1–20) 8 (2–37) 8 (5–87) 0.443
Cystatin C (μg/g creat) 39 (17–777) 37 (20–77) 14 (8–212) 0.544
Calbindin (μg/g creat) 36 (4–168) 27 (6–116) 34 (9–148) 0.815
β2-microglobulin (μg/g creat) 156 (7–1553) 76 (5–239) 19 (3–1345) 0.773
IL-18 (ng/g creat) 23 (15–44) 29 (14–170) 53 (13–163) 0.916
Clusterin (μg/g creat) 9 (1–83) 13 (4–26) 4 (1–18) 0.370
Values are expressed as median and IQR.
AKI, acute kidney injury.
doi:10.1371/journal.pone.0128145.t004
Table 5. Values of urinary biomarkers in patients categorized according to the absence or presence of AKI and type of AKI.
Urinary Biomarkers No AKI(n = 16) Prerenal (n = 12) HRS Type I (n = 15) ATN(n = 12) p
NGAL (μg/g creat) 30 (17–41) 36 (26–125) 104 (58–208) 1807 (494–3716) < 0.0001
IL-18 (ng/g creat) 21 (16–35) 16 (14–36) 18 (10–29) 150 (58–259) < 0.0001
Albumin (mg/g creat) 3 (1–7) 9 (1–77) 16 (8–46) 324 (53–380) < 0.0001
TFF-3 (μg/g creat) 582 (367–1665) 2300 (323–2720) 1893 (840–2715) 5810 (2778–13332) < 0.0001
MCP-1 (μg/g creat) 0.2 (0.1–1.4) 0.9 (0.2–2.5) 3 (1–6) 4 (1–14) < 0.0001
Osteopontin (μg/g creat) 1456 (715–3210) 2914 (1847–8382) 5471 (2959–11983) 8337 (4019–14466) < 0.0001
Calbindin (μg/g creat) 71 (26–150) 5 (2–34) 25 (8–58) 118 (37–324) 0.010
GST-π (μg/g creat) 3 (1–16) 3 (1–7) 4 (2–21) 50 (9–169) 0.012
KIM-1 (μg/g creat) 0.5 (0.3–1.4) 0.5 (0.1–1.1) 1.2 (0.5–2.8) 1.7 (0.9–5.1) 0.015
Cystatin C (μg/g creat) 24 (12–45) 21 (15–153) 27 (10–47) 115 (39–1552) 0.023
β2-microglobulin (μg/g creat) 51 (13–140) 50 (4–336) 19 (3–239) 1094 (41–26709) 0.033
Clusterin (μg/g creat) 9 (2–38) 1 (0.9–12) 7 (2–26) 20 (6–255) 0.103
Values are expressed as median and IQR.
AKI, acute kidney injury; HRS, hepatorenal syndrome; ATN, acute tubular necrosis.
Values in healthy subjects are as follows: NGAL 33 (23–47), IL-18 18 (11–45), Albumin 1 (0–2), TFF-3 678 (466–951), MCP-1 0.1 (0.04–0.2), Osteopontin
1416 (900–2025), Calbindin 20 (5–58), GST-π 0.9 (0.3–5.9), KIM-1 0.2 (0.1–0.4), Cystatin C 32 (8–57), β2-microglobulin 95 (9–132), Clusterin 10 (2–79).
doi:10.1371/journal.pone.0128145.t005
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of patients without ACLF (Table 7). Moreover, NGAL, osteopontin, albumin, MCP-1, and
TFF-3 were very accurate in ACLF diagnosis with an AUCROC greater than 0.75. By contrast,
there were no significant differences between patients with and without ACLF with respect to
the urinary concentrations of cystatin C, clusterin, IL-18, β2-microglobulin, and calbindin.
Due to the design of the study which was based on selection of patients according to pres-
ence or absence of AKI, the vast majority of patients with ACLF had associated AKI (33 out of
34). Therefore, the possibility existed that the increased urinary levels of some of the biomark-
ers could be explained largely by the associated AKI. To further explore this issue we studied
an additional group of patients with ACLF but without associated AKI. The characteristics of
this group of patients are shown in Table B in S1 File. We then compared urinary biomarkers
in all patients of the study categorized in 4 groups: patients without ACLF with or without
AKI, and patients with ACLF with or without AKI. As shown in Table 8, urinary biomarkers
Table 6. AUCROC of all biomarkers for the differential diagnosis of ATN vs other types of AKI.
Urinary Biomarkers Diagnosis of ATN vs other types of AKIAUCROC (95% CI) p Cut-off level Sensitivity Speciﬁcity
NGAL (μg/g creat) 0.957 (0.891–1.00) < 0.0001 294 92% 89%
IL-18 (ng/g creat) 0.920 (0.836–1.00) < 0.0001 51 83% 89%
Albumin (mg/g creat) 0.858 (0.733–0.983) < 0.0001 86 75% 85%
TFF-3 (μg/g creat) 0.824 (0.667–0.981) 0.001 3040 75% 81%
GST-π (μg/g creat) 0.812 (0.647–0.976) 0.002 8.27 83% 78%
β2-microglobulin (μg/g creat) 0.790 (0.624–0.956) 0.004 410 67% 85%
Calbindin (μg/g creat) 0.784 (0.638–0.930) 0.005 41.4 75% 74%
Cystatin C (μg/g creat) 0.762 (0.594–0.931) 0.010 44.5 75% 70%
Clusterin (μg/g creat) 0.704 (0.502–0.906) 0.045 16.2 67% 78%
KIM-1 (μg/g creat) 0.704 (0.518–0.889) 0.045 1.6 67% 74%
MCP-1 (μg/g creat) 0.685 (0.490–0.881) 0.068 2.2 67% 59%
Osteopontin (μg/g creat) 0.639 (0.442–0.836) 0.171 5680 58% 59%
ATN, acute tubular necrosis; AKI, acute kidney injury.
doi:10.1371/journal.pone.0128145.t006
Table 7. Values of urinary biomarkers in patients categorized according to the absence or presence of Acute-on-chronic liver failure (ACLF).
Urinary Biomarkers No ACLF (n = 21) ACLF (n = 34) p Diagnosis of ACLF AUCROC (95% CI)
NGAL (μg/g creat) 32 (19–40) 165 (67–676) < 0.0001 0.878 (0.787–0.969)
Osteopontin (μg/g creat) 1669 (820–2987) 5560 (3365–11028) < 0.0001 0.839 (0.715–0.963)
Albumin (mg/g creat) 2 (1–7) 41 (11–281) < 0.0001 0.829 (0.718–0.940)
MCP-1 (μg/g creat) 0.2 (0.1–1.4) 2.2 (1–6.3) < 0.0001 0.812 (0.691–0.934)
TFF-3 (μg/g creat) 649 (368–1932) 2574 (902–4239) 0.001 0.768 (0.641–0.894)
KIM-1 (μg/g creat) 0.4 (0.1–1) 1.3 (0.6–3.4) 0.002 0.746 (0.614–0.879)
GST-π (μg/g creat) 2 (1–6) 8 (3–47) 0.008 0.713 (0.571–0.854)
Cystatin C (μg/g creat) 21 (15–43) 40 (13–184) 0.072 0.646 (0.502–0.789)
Clusterin (μg/g creat) 3 (1–14) 13 (3–40) 0.074 0.644 (0.493–0.795)
IL-18 (ng/g creat) 23 (16–34) 31 (14–165) 0.299 0.584 (0.433–0.735)
β2-microglobulin (μg/g creat) 52 (11–149) 90 (5–756) 0.341 0.577 (0.426–0.728)
Calbindin (μg/g creat) 49 (6–149) 32 (9–143) 0.876 0.487 (0.328–0.647)
Values are expressed as median and IQR.
ACLF, Acute-on-chronic liver failure
doi:10.1371/journal.pone.0128145.t007
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associated with the presence of ACLF were NGAL, osteopontin, albumin, and TFF3. By con-
trast, MCP-1, KIM-1, and GST-π were only significantly increased in patients with ACLF in
the setting of associated AKI, which suggests that these biomarkers were likely related to
kidney injury.
Biomarkers and relationship with survival
Finally, a number of biomarkers were related to the occurrence of death within a 3 month peri-
od (Table 9). The biomarkers with the highest AUCROC of mortality were NGAL, osteopon-
tin, albumin, and MCP-1.
Table 8. Values of urinary biomarkers in patients categorized according to the absence or presence of Acute-on-chronic liver failure (ACLF) and
Acute kidney injury (AKI).
Urinary Biomarkers No ACLF without AKI
(n = 15)
No ACLF with AKI
(n = 6)
ACLF without AKI
(n = 11)
ACLF with AKI
(n = 33)
p
NGAL (μg/g creat) 32 (16–43) 31 (25–89) 147 (41–233) 187 (75–688) < 0.0001
Osteopontin (μg/g creat) 1444 (664–2541) 1970 (1445–17478) 3990 (2033–5662) 5650 (3230–11346) < 0.0001
Albumin (mg/g creat) 1.8 (0.8–6.6) 1.8 (1.2–32) 50 (24–118) 42 (10–293) < 0.0001
TFF-3 (μg/g creat) 649 (338–1708) 1383 (369–3113) 3117 (1327–3856) 2611 (1052–4410) 0.002
MCP-1 (μg/g creat) 0.1 (0.1–1.2) 0.7 (0.1–2.9) 0.8 (0.2–2.3) 2.3 (1–6.9) 0.001
KIM-1 (μg/g creat) 0.4 (0.3–1.4) 0.3 (0.1–0.9) 0.7 (0.3–1.2) 1.3 (0.6–3.0) 0.016
GST-π (μg/g creat) 2.4 (0.6–6.4) 1.4 (0.8–41) 3.2 (2.8–53) 7.6 (3.2–43) 0.069
Clusterin (μg/g creat) 8 (1.7–33) 1.1 (0.8–3.2) 16 (0.3–39) 13 (2.8–35) 0.097
Cystatin C (μg/g creat) 21 (11–47) 21 (15–51) 34 (20–44) 42 (13–193) 0.308
Calbindin (μg/g creat) 58 (26–151) 5 (4–1216) 58 (29–154) 31 (8–144) 0.366
IL-18 (ng/g creat) 19 (16–30) 27 (15–39) 34 (26–196) 29 (14–150) 0.368
β2-microglobulin (μg/g
creat)
52 (13–144) 50 (7–215) 121 (43–218) 103 (5–785) 0.598
Values are expressed as median and IQR.
ACLF, Acute-on-chronic liver failure; AKI, acute kidney injury.
doi:10.1371/journal.pone.0128145.t008
Table 9. Values of urinary biomarkers in patients categorized according to survival at 3 months*.
Urinary Biomarkers Alive (n = 37) Dead (n = 14) p Mortality AUCROC (95% CI)
NGAL (μg/g creat) 38 (27–108) 458 (114–3661) < 0.0001 0.876 (0.782–0.971)
Osteopontin (μg/g creat) 2704 (1442–5391) 8759 (4770–16455) 0.001 0.809 (0.683–0.935)
Albumin (mg/g creat) 7 (2–37) 113 (15–333) 0.001 0.797 (0.656–0.938)
MCP-1 (μg/g creat) 1.1 (0.1–2.4) 3.4 (2.0–9.3) 0.001 0.795 (0.665–0.925)
GST-π (μg/g creat) 4 (1–15) 26 (5–58) 0.010 0.736 (0.599–0.872)
KIM-1 (μg/g creat) 0.6 (0.3–1.6) 2.1 (0.6–5.4) 0.021 0.710 (0.540–0.881)
TFF-3 (μg/g creat) 1538 (483–2673) 3208 (899–8700) 0.045 0.683 (0.506–0.860)
Cystatin C (μg/g creat) 26 (12–47) 57 (20–344) 0.095 0.653 (0.482–0.823)
IL-18 (ng/g creat) 18 (15–39) 62 (20–180) 0.100 0.651 (0.450–0.851)
β2-microglobulin (μg/g creat) 60 (6–211) 73 (15–7793) 0.410 0.575 (0.389–0.761)
Clusterin (μg/g creat) 9 (1–30) 11 (3–111) 0.423 0.573 (0.388–0.758)
Calbindin (μg/g creat) 49 (8–129) 27 (9–244) 1 0.500 (0.318–0.682)
Values are expressed as median and IQR.
*Three patients were lost to follow-up and one patient was transplanted during the 3-month follow-up period.
doi:10.1371/journal.pone.0128145.t009
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Discussion
The current study was designed to evaluate the potential role of a panel of urinary biomarkers
in the assessment of clinical outcomes in patients with cirrhosis. The novelty of this study with
respect to previous studies published examining urinary biomarkers in patients with cirrhosis
is twofold [11–15]. First, the analytical approach used was an analysis of a panel of biomarkers
instead of just one or few biomarkers. This was possible with the use of the multiplex technolo-
gy, which allows testing for a significant number of biomarkers using a small urine volume.
Second, the current study analyzed not only the potential usefulness of biomarkers in the as-
sessment of AKI, but also its possible effectiveness in the assessment of the recently described
syndrome of ACLF and survival.
The first outcome analyzed was the presence, severity, and type of AKI. Urinary biomarkers
reflect typically, but not exclusively, alterations in kidney function such as impairment of glo-
merular filtration rate and/or tubular injury or dysfunction [6,7]. Not unexpectedly, some bio-
markers were found to be increased in patients with AKI compared to those of patients
without AKI, including NGAL and albumin. NGAL has previously been reported as increased
in the setting of AKI in cirrhosis [11–15]. Interestingly, the urinary levels of some biomarkers
not evaluated in previous studies, such as TFF-3, MCP-1, and osteopontin were higher in pa-
tients with AKI compared to those of patients without AKI.
In the clinical setting, the diagnosis of AKI is made on the basis of changes in serum creati-
nine concentration according to pre-established criteria [17]. Therefore, there is no need for the
use of biomarkers to diagnose AKI. By contrast, the usefulness of biomarkers in the field of cir-
rhosis may be particularly relevant in the differential diagnosis of the type of AKI, especially in
distinguishing ATN from Prerenal-AKI or HRS. Theoretically, the urinary concentration of
biomarkers which are up-regulated in the setting of tubular injury should be increased in pa-
tients with ATN compared to patients with Prerenal-AKI. Moreover, HRS should also theoreti-
cally display low levels of biomarkers in urine because of the anticipated lack of injury in the
tubular cells [22,23]. Therefore, we analyzed the predictive value of all biomarkers included in
the panel in the differential diagnosis between ATN and Prerenal-AKI or type-1 HRS. The ma-
jority of biomarkers analyzed had statistically significant predictive value in the diagnosis of
ATN, except for MCP-1 and osteopontin. The biomarkers with the highest predictive value
were NGAL, IL-18, albumin, TFF-3, and GST-π. The NGAL findings are consistent with those
of a previous study from our group as well as from other groups [11–13]. The level of NGAL
with the highest sensitivity and specificity for the diagnosis of ATN found in the current study
was 294 μg/g creatinine. Taken together, the findings of these studies suggest that uNGAL is of
value in the differential diagnosis of ATN from functional types of AKI, including Prerenal-
AKI and HRS. Future studies should therefore aim at evaluating the incorporation of uNGAL
determination in the algorithm of differential diagnosis of AKI in cirrhosis. This biomarker-
based algorithm could be useful in guiding therapeutic decisions in these patients. Biomarkers
other than NGAL that showed high accuracy (AUCROC> 0.8) in ATN prediction were IL-18,
albumin, TFF-3, and GST-π. The first two biomarkers have also been reported to have high sen-
sitivity and specificity in ATN diagnosis in a recent study [13]. The possible role of TFF-3 and
GST-π in ATN diagnosis has to our knowledge not been reported previously and would require
confirmation in future studies. TFF-3 is a member of the trefoil factor peptide family that in the
kidney it is predominantly produced by epithelial cells of the proximal and distal tubules and
cortical collecting duct that appears to play a role in tubular regeneration early after injury [24].
Information on the potential usefulness of TFF-3 as urinary biomarker of kidney injury is very
scant [25]. Interestingly, a recent study has shown that the plasma levels of TFF-3 are increased
in patients with AKI before liver transplantation and return to normal values following recovery
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of kidney function after transplantation [26]. GST-π belongs to the family of glutathione-S-
transferases that are ubiquitous enzymes that act by detoxifying free radicals. They are present
in a large variety of tissues, but the α and π isoforms are very abundant in kidney tubules and
are overexpressed after kidney injury [27]. Evidence indicates that urinary GST-π levels are
helpful for early diagnosis and predicting progression of ATN after cardiac surgery [28]. On the
other hand, the potential usefulness of urinary KIM-1 in the diagnosis of ATN that has been re-
ported in nephrology studies in non-selected patient population was not confirmed in the cur-
rent study in patients with cirrhosis, as this biomarker had one of the lowest AUCROC curves
of all biomarkers analyzed. With the results of the current study, however, it is not known
whether the increase in urinary biomarkers in patients with cirrhosis and ATN was exclusively
due to ATN or could, at least in part, be related to the concomitant presence of cirrhosis. Unfor-
tunately, a group of patients with ATN without cirrhosis was not available for study.
It is interesting to emphasize that while the urinary biomarkers reported above were helpful
in differentiating the type of AKI (ATN vs other), there were no significant differences in bio-
marker levels according to AKI stage (Table 4). This suggests that in cirrhosis, urinary bio-
marker concentrations are more dependent on the etiology than on the severity of AKI, as
assessed by AKI stage.
An interesting and novel finding of the current study was that some of the urinary biomark-
ers studied were increased in patients with ACLF compared to levels in patients with acute de-
compensation of cirrhosis without ACLF, and showed high predictive accuracy of ACLF
diagnosis. ACLF is a syndrome recently described that occurs in patients with an acute decom-
pensation of cirrhosis and is characterized by the presence of failure of different organs/systems
associated with high short-term mortality rate [4]. Although the pathogenesis of this syndrome
is not fully understood, most patients with ACLF show signs of systemic inflammatory re-
sponse which is thought to play a role in the development of organ failures. In some patients
the inflammatory response is related to bacterial infections while in others it occurs in the ab-
sence of any detectable infection [29–31]. Potential useful biomarkers for ACLF included
NGAL, osteopontin, albumin, MCP-1, KIM-1, and TFF-3. Interestingly, these biomarkers were
also highly predictive of 3-month survival. The value of NGAL as biomarker of ACLF is consis-
tent with the results found in a large population of patients from the Canonic study showing
that uNGAL levels correlated with the presence and severity of ACLF and showed independent
predictive value of short-term survival [32]. Moreover, preliminary studies from our laboratory
show that the lipocalin-2 gene expression, the gene responsible for NGAL synthesis, is marked-
ly upregulated in the liver of patients with ACLF compared to the expression found in the liver
of patients with acute decompensation of cirrhosis without ACLF (unpublished observations).
These findings are in keeping with those of several recent experimental studies showing up-reg-
ulation of the lipocalin-2 gene following hepatocyte injury, bacterial infection or during liver
regeneration [8–10]. Taken together, these results suggest that the increased NGAL levels in
the urine of patients with ACLF may derive not only from an injured kidney but also from the
liver. Moreover, there is the possibility, not yet tested, of the contribution of leukocytes to in-
creased uNGAL levels, because gene expression may also be upregulated as a consequence of
leukocyte activation. The association between MCP-1 and KIM-1 and ACLF was related to the
existence of associated AKI. It is well known that KIM-1 is overexpressed in the kidney as a
consequence of different types of injury and its urinary levels are increased in this condition
[7]. Likewise, MCP-1 expression is increased in the kidney in experimental models of AKI
[33]. Therefore, the possibility exists that MCP-1 found in urine in patients with ACLF may be
in part from renal origin.
The potential role of osteopontin and TFF-3 as biomarkers of ACLF deserves a specific
comment. Osteopontin is a pleotropic protein that is expressed in a number of cell types,
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including osteoblasts, chondrocytes, inflammatory cells (macrophages, dendritic cells and T-
cells), kidney cells, hepatocytes, and hepatic stellate cells. Osteopontin secreted from the cells
acts through several of receptors, including various integrins and CD44, regulating a number
of cellular processes such as bone mineralization, tissue remodeling, and inflammation [34].
Several lines of evidence indicate that osteopontin plays a role in conditions characterized by
chronic inflammatory state. In the liver, increased osteopontin expression has been found in
several experimental models of liver diseases as well as in human diseases, particularly alcoholic
hepatitis and NASH [35,36]. Osteopontin has proinflammatory and profibrogenic properties
in the liver. Investigations from our laboratory indicate that osteopontin is overexpressed in
the liver of patients with alcoholic hepatitis and its expression correlates with inflammatory ac-
tivity within the liver and disease severity [35]. Similar findings have been found in patients
with non-alcoholic steatohepatitis [36]. On this background, the findings of the current study
of increased urinary osteopontin levels in patients with ACLF are consistent with the existence
of a marked inflammatory reaction in this condition [4]. Whether the high urinary levels are
secondary to an increased systemic production of osteopontin, either derived from the liver
and/or from inflammatory cells, or reflect a theoretically increased expression within the kid-
neys or a combination thereof is not known. The potential role of osteopontin as biomarker of
ACLF should be explored in future studies.
Several lines of evidence indicate that TFF-3 is a protective factor in the intestinal epitheli-
um and plays a beneficial role in inflammatory bowel diseases in humans [37]. TFF-3 is also ex-
pressed in the biliary epithelium and its expression increases in conditions of injury of biliary
epithelial cells [38,39]. The origin of the increased urine levels of TFF-3 in patients with ACLF
found in the current study is unknown. Nevertheless, the potential role of TFF-3 as biomarker
in this condition deserves investigation in future studies. A final interesting observation of the
current study is the markedly increased urinary levels of albumin in patients with ACLF both
with and without AKI. Previous studies have shown that urine albumin could be a potential
biomarker of AKI in patients with cirrhosis [13]. Our study extends these observations by
showing that patients with ACLF have increased urine albumin levels regardless of the pres-
ence of AKI. This suggests a potential role for urine albumin as biomarker of ACLF. Moreover,
urine albumin was also associated with prognosis. These findings deserve investigation in larg-
er series of patients.
In summary, in the current study we found an association of several urinary biomarkers
with different outcomes in patients with cirrhosis. A number of biomarkers were associated
with the presence of ATN and were useful in distinguishing ATN from other causes of AKI.
The best biomarkers in the differential diagnosis of ATN were NGAL, IL-18, albumin, TFF-3,
and GST-π. On the other hand, we found a number of biomarkers associated with ACLF, in-
cluding among others NGAL, osteopontin, albumin, and TFF-3. The increased levels of
NGAL, osteopontin, and TFF-3 point towards the importance of inflammatory mediators as
biomarkers in this condition. Finally, the same four biomarkers were associated with 3-month
survival. The application of these biomarkers in clinical practice and its potential usefulness in
assessing outcomes in patients with cirrhosis should be evaluated in prospective studies includ-
ing large patient populations.
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